Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
January 30, 2018 at 20:03 PM EST
Investment manager Polen Capital is bullish on Regeneron Pharmaceuticals (REGN), which has six FDA-approved medicines and numerous product candidates in a range of diseases.
